Search
Spruce Biosciences Inc
SPRBAdd to Watchlist
42.830USD
-0.540-1.25%
Close 07-31 16:00（ET）Quotes delayed by 15 min
58.76MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Spruce Biosciences Inc is 8.75, ranking 61 out of 385 in the Biotechnology & Medical Research industry. The average price target is 209.50, with a high of 259.00 and a low of 160.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
151.000
Target Price
+264.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Spruce Biosciences Inc
SPRB
8
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Spruce Biosciences Inc's price target?
Analysts forecast that Spruce Biosciences Inc's price target is USD 209.50, with the highest forecast at USD 259.00 and the lowest forecast at USD 160.00.
How have Spruce Biosciences IncSPRB's recent earnings per share performed?
The market expectation was USD -8.94, while Spruce Biosciences IncSPRB's earnings per share (EPS) for the previous quarter was USD -11.28. EPS for the next quarter is expected at USD -5.80.
What is the analyst rating for Spruce Biosciences Inc?
Based on the ratings of Spruce Biosciences Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.